The incremental HCC risk associated with decreasing baseline HBV DNA levels was consistently observed when baseline alpha-fetoprotein (AFP) level or antiviral treatment type (TDF or entecavir) was further adjusted in the multivariable analysis. This evidence concerns the gene AFP and hepatocellular carcinoma.